By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
During the surgical procedure, the extracorporeal circulation machine, one of the most advanced technologies used, takes the place of the heart’s pumping action and the lungs’ ability to breathe. During cardiac arrest, normal systemic, myocardial, and cerebral blood flows may be maintained by extracorporeal circulation.
Its capacity to reestablish spontaneous circulation after prolonged cardiac arrest and failure in conventional cases has been demonstrated through experimental studies on animals and human cardiac arrest victims and they have succeeded in it thus took the invention forward.
However, practical constraints limit extracorporeal circulation’s clinical application. When trained personnel and ready-to-use, preferably pre primed, extracorporeal systems are immediately available, it may be possible in the operating room, intensive care unit, or catheterization laboratory.
However, there are currently no convincing data on human victims that serve as a solid foundation for the more widespread clinical use of extracorporeal techniques in other settings.
The Global Extracorporeal circulation system market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
COMICS has launched the and present intrusive extracorporeal flow. The primary benefit of the inherent characteristics of MiECC systems is that they facilitate the most effective application of cardiovascular physiology to intraoperative perfusion and ultimately combine all three operative disciplinary techniques into a single strategy; MiECC’s combined holistic effect may be considered a treatment option for cardiovascular diseases.
MiECC outperforms conventional CPB (cCPB) in terms of reducing haemodilution and better preserving haematocrit, thereby reducing the need for perioperative blood transfusion in the current era of evidence-based medicine.
Current clinical evidence justifies the superiority of MiECC over cCPB in this regard, and it is literally unanimous. The EACTS/EACTA Task Force was recently compelled by these findings to incorporate MiECC as an intraoperative strategy for managing blood conservation and maintaining haemostasis in adult cardiac surgery.
In addition, MiECC significantly lowers postoperative atrial fibrillation, enhances renal and myocardial protection reduces cerebral gaseous microembolization, attenuates the systemic inflammatory response, and preserves end-organ function.
